Chu; Seung Y.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Chu; Seung Y..The latest application filed is for "novel compositions and methods for treating ige-mediated disorders".
- Chu; Seung Y. - Cypress CA
- Chu; Seung Y. - Monrovia CA
- Chu; Seung Y. - Upland CA
| Patent | Date |
|---|---|
| Heterodimeric antibodies that bind CD3 and CD38 Grant 11,352,442 - Bernett , et al. June 7, 2 | 2022-06-07 |
| Bispecific antibodies that bind to CD38 and CD3 Grant 10,858,451 - Bernett , et al. December 8, 2 | 2020-12-08 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20200332024 - Desjarlais; John R. ; et al. | 2020-10-22 |
| Heterodimeric Antibodies That Bind Cd3 And Cd38 App 20200199251 - Bernett; Matthew J. ; et al. | 2020-06-25 |
| Heterodimeric Antibodies That Bind Cd3 And Cd38 App 20180305465 - Stevens; Jennitte Leann ; et al. | 2018-10-25 |
| Bispecific Antibodies That Bind to CD38 and CD3 App 20180094079 - Bernett; Matthew J. ; et al. | 2018-04-05 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20170335013 - Desjarlais; John R. ; et al. | 2017-11-23 |
| Compositions and methods for treating IgE-mediated disorders Grant 9,617,348 - Desjarlais , et al. April 11, 2 | 2017-04-11 |
| Optimized anti-CD30 antibodies Grant 9,574,006 - Lazar , et al. February 21, 2 | 2017-02-21 |
| Compositions and methods for treating IgE-mediated disorders Grant 9,540,451 - Desjarlais , et al. January 10, 2 | 2017-01-10 |
| Compositions and methods for treating IgE-mediated disorders Grant 9,266,966 - Desjarlais , et al. February 23, 2 | 2016-02-23 |
| Compositions and methods for treating IgE-mediated disorders Grant 9,221,916 - Desjarlais , et al. December 29, 2 | 2015-12-29 |
| Compositions and methods for treating IgE-mediated disorders Grant 9,062,117 - Desjarlais , et al. June 23, 2 | 2015-06-23 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20150139985 - DESJARLAIS; JOHN ; et al. | 2015-05-21 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20150093379 - DESJARLAIS; JOHN ; et al. | 2015-04-02 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20130203966 - DESJARLAIS; JOHN R. ; et al. | 2013-08-08 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20130203967 - DESJARLAIS; JOHN R. ; et al. | 2013-08-08 |
| Novel Compositions and Methods for Treating IgE-Mediated Disorders App 20130177553 - Desjarlais; John ; et al. | 2013-07-11 |
| Compositions and methods for treating IgE-mediated disorders Grant 8,435,517 - Desjarlais , et al. May 7, 2 | 2013-05-07 |
| Optimized Anti-CD30 Antibodies App 20120014943 - Lazar; Gregory Alan ; et al. | 2012-01-19 |
| Optimized anti-CD30 antibodies Grant 7,973,136 - Lazar , et al. July 5, 2 | 2011-07-05 |
| NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS App 20100080814 - Desjarlais; John R. ; et al. | 2010-04-01 |
| Optimized Anti-Cd30 Antibodies App 20080267976 - Lazar; Gregory Alan ; et al. | 2008-10-30 |
| Optimized Anti-cd30 Antibodies App 20070166309 - Lazar; Gregory Alan ; et al. | 2007-07-19 |
| Optimized anti-CD30 antibodies App 20070148171 - Lazar; Gregory Alan ; et al. | 2007-06-28 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 